CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands		Common Stock	Additional Paid-in Capital Adjustment	Additional Paid-in Capital	Accumulated Deficit Adjustment	Accumulated Deficit	Adjustment	Total
Beginning balance at Dec. 31, 2022		$ 54		$ 379,167		$ (389,861)		$ (10,640)
Beginning balance (in shares) at Dec. 31, 2022	[1]	53,790,167
Issuance of common stock under the Sales Agreement, net		$ 13		23,941				23,954
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	12,560,150
Convertible notes conversions		$ 5		7,778				7,783
Convertible notes conversions (in shares)	[1]	4,691,623
Share-based compensation related to stock options				812				812
Share-based compensation related to restricted stock awards				172				172
Exercise of warrants				712				712
Exercise of warrants (in shares)	[1]	538,822
Net income (loss) for the period						16,208		16,208
Ending balance at Jun. 30, 2023		$ 72		412,582		(373,653)		39,001
Ending balance (in shares) at Jun. 30, 2023	[1]	71,580,762
Beginning balance at Mar. 31, 2023		$ 62		393,938		(392,992)		1,008
Beginning balance (in shares) at Mar. 31, 2023	[1]	62,002,649
Issuance of common stock under the Sales Agreement, net		$ 5		9,716				9,721
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	4,347,668
Convertible notes conversions		$ 5		7,778				7,783
Convertible notes conversions (in shares)	[1]	4,691,623
Share-based compensation related to stock options				359				359
Share-based compensation related to restricted stock awards				79				79
Exercise of warrants				712				712
Exercise of warrants (in shares)	[1]	538,822
Net income (loss) for the period						19,339		19,339
Ending balance at Jun. 30, 2023		$ 72		412,582		(373,653)		39,001
Ending balance (in shares) at Jun. 30, 2023	[1]	71,580,762
Beginning balance at Dec. 31, 2023		$ 73		415,045		(381,549)		33,569
Beginning balance (in shares) at Dec. 31, 2023	[1]	72,952,124
Share-based compensation related to stock options				833				833
Share-based compensation related to restricted stock awards				1,146				1,146
Share-based compensation related to restricted stock awards (in shares)	[1]	340,550
Net income (loss) for the period						(6,798)		(6,798)
Ending balance (ASU 2020-06) at Jun. 30, 2024			$ (393)		$ 224		$ (169)
Ending balance at Jun. 30, 2024		$ 73		416,631		(388,123)		28,581
Ending balance (in shares) at Jun. 30, 2024	[1]	73,292,674
Beginning balance at Mar. 31, 2024		$ 73		415,633		(385,920)		29,786
Beginning balance (in shares) at Mar. 31, 2024	[1]	73,052,124
Share-based compensation related to stock options				333				333
Share-based compensation related to restricted stock awards				665				665
Share-based compensation related to restricted stock awards (in shares)	[1]	240,550
Net income (loss) for the period						(2,203)		(2,203)
Ending balance (ASU 2020-06) at Jun. 30, 2024			$ (393)		$ 224		$ (169)
Ending balance at Jun. 30, 2024		$ 73		$ 416,631		$ (388,123)		$ 28,581
Ending balance (in shares) at Jun. 30, 2024	[1]	73,292,674

[1] Common stock, $0.001 par value; Authorized – as of June 30, 2024 and December 31, 2023 – 185,000,000 shares.